Status:
COMPLETED
Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer
Lead Sponsor:
Mansoura University
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This retrospective study aimed at assessment of different patterns (morphological and pathological) of tumor recurrence found at first evaluation after BCG induction therapy (3 months cystoscopy) for ...
Detailed Description
Bladder cancer (BCa) is the second most common genitourinary malignancy with approximately 75-85% of all patients with BCa present at diagnosis a non-muscle invasive bladder cancer (NMIBC) (Ta, T1 and...
Eligibility Criteria
Inclusion
- Patients for who complete TURBT, was carried out
- Intermediate and high risk NMIBC.
- Patients who received full induction BCG regimen (6 weekly doses).
- Patients completed at least 12 months follow up after 3 months cystoscopy.
Exclusion
- Patients who received incomplete induction BCG regimen (less than 6 weekly doses)
- Patients with incomplete (less than 12 months) follow up.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 18 2020
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT04319263
Start Date
March 1 2020
End Date
March 18 2020
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology and Nephrology Center
Al Mansurah, Egypt, 35516